Citations

Clear

2129 citation(s) found for "Fu, Christine".

Even the presence of minimal changes in regional wall motion abnormalities with exercise stress echocardiography predicts MACE and all-cause mortality in patients with previous chest radiotherapy
Manotas, Rafael, Santos-Patarroyo, Sebastián , Acevedo, Andres Daryanani, Collantes, Diana, Ricaurte, Carolina, Hoppenworth, Jenna, Thicke, Lori, Smith, D R, Klassen, Christine L. , Haddad, Tufia C. , Peethambaram, Prema P. , Mutter, Robert W. , Villarraga, Hector R. , Daryanani, Andres , Patarroyo, Sebastian Santos , Manotas, R Toro, Carroll, J L, Stan, Daniela

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.2709 Get It

Abstract Background Exercise stress echocardiography (ESE) is a non-invasive, radiation-free, and widely available technique that has demonstrated a reliable accuracy for the detection of coronary artery disease (CAD). Chest radiotherapy (RT) is associated with accelerated age-related atherosclerosis and fibrosis in a dose-dependent manner. ESE plays a role as a screening tool of RT induced heart disease, however, the prognostic value of changes in regional wall motion abnormalities in this population during ESE has not been evaluated. Methods This is a retrospective cohort study of breast cancer survivors treated with adjuvant RT that underwent ESE from 2000-2020 after treatment completion. Outcomes evaluated were: major adverse cardiovascular events (MACE: cardiovascular death, myocardial infarction, revascularization and stroke); and all-cause mortality. A univariate analysis was performed to characterize the population. Continuous variables were presented as means ± standard deviation (SD) or median with quartile 1 and 3 (Q1, Q3), and categorical variables as numbers and percentages. A Cox regression model adjusted by age and cardiovascular risk factors was used to evaluate variables associated with outcomes, and a time to first event approach was used. A p-value of <0.05 was considered statistically significant. Results From 2000-2020, 507 patients, with a mean age 66 ± 10 years, underwent ESE at a median of 5.8 years after RT completion. The most prevalent comorbidities were dyslipidemia (59%), HTN (55%) and obesity (37%). 55% underwent RT for left-sided breast cancer and 45% for right-sided, and median RT dose was 6000 cGy. Baseline characteristics are presented in Table 1. Most patients underwent Bruce Protocol (92%). Patients exercised a mean time of 6.6 minutes achieving 7.3 METS and 109% of functional aerobic capacity (Table 2). At a median follow up of 7.8 years, 61 MACE events occurred. Predictors of MACE were double product, baseline and stress EF, baseline and peak regional wall motion abnormalities (RWMA), development of new ischemic RWMA, inability to reach 85% of maximum HR, and an abnormal EF response with stress after adjusting for age, HTN, DM, smoking history, dyslipidemia, obesity, prior MI and cancer staging (Fig 1). Predictors of all-cause mortality were METS, LV mass index, baseline and peak RWMA, development of new ischemic RWMA and an abnormal EF change with stress even after adjusting for variables described previously (Fig 2). Conclusions The development of new or worsening RWMA of just 2 segments with stress, was a significant predictor of MACE and all-cause mortality in a large cohort of breast cancer survivors undergoing multidisciplinary management including adjuvant RT. Special emphasis on management of cardiovascular comorbidities and closer surveillance are recommended for these patients.
Hidden risk of gadolinium-based contrast agents during interventional pain medicine procedures: a retrospective chart review
Eldrige, Jason S. , Provenzano, David , Abdel-Latif, Tesneem, Klasová, Johana , Furtado-Pessoa-de-Mendonca, Laura , Yan, Dan , Hunt, Christine , Hallo-Carrasco, Alejandro, Eldrige, Jason, Provenzano, David Anthony , Hunt, Christine , Hallo‐Carrasco, Alejandro , Gonzalez‐Estrada, Alexei

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 11, 2023 | Volume: 49 | Issue: 10 | Pages: 751-756

10.1136/rapm-2023-104952 | PMID 37951601 Get It

Introduction Epidural steroid injections and epidural blood patches commonly involve the injection of a small amount of radiocontrast media under fluoroscopy to properly identify the target tissue or anatomic space and prevent off-target or intravascular delivery of therapeutic or diagnostic drugs. Iodinated low osmolar non-ionic contrast media is the standard preparation used as it is considered safe and cost-effective, but gadolinium-based preparations have been used as an alternative for patients with an ‘iodine’-related or radiocontrast media allergy label to prevent hypersensitivity reactions. The risk of neurotoxic events when gadolinium is inadvertently injected into the intrathecal space has been reported in recent years, raising concerns when gadolinium-based contrast media is used in lieu of iodinated low osmolar non-ionic contrast media. Methods A retrospective review was conducted of patients who received gadolinium-based contrast media for procedures with risk of inadvertent intrathecal access from January 1, 2019 to May 1, 2022. Information on patient demographics, allergy label information, and procedure description was documented for all patients who received gadolinium-based contrast media for axial spine procedures (including epidural steroid injections, epidural blood patch procedures, and selective nerve root blocks), and all side effects reported within 1 month of the procedure were recorded. Saved fluoroscopy images of all procedures for which there was concern for possible gadolinium-based contrast media-related side effect were reviewed for evidence of inadvertent intrathecal gadolinium-based contrast media administration. Descriptive statistical analysis was performed using REDCap and IBM SPSS Statistics V.28. Results We identified 508 patients who received gadolinium-based contrast media during a fluoroscopically guided axial spine procedure. These patients underwent 697 epidural procedures and 23 patients were identified as experiencing an adverse event that could be consistent with possible, probable, or clear signs of exposure to intrathecal gadolinium. Our calculated adverse event rate was 3.3%. Ten patients required additional medical evaluation or treatment. Discussion Almost all patients in our cohort had an allergy label on their chart that guided the provider to switch to gadolinium-based contrast media, but most were incomplete, ill-defined, or related to allergy to iodine but not iodinated contrast media. Such practice is not recommended based on current guidelines. The current study raises concern regarding the use of gadolinium-based contrast media in axial spine procedures, with the risk of potential severe adverse events, without evidence-based need for avoiding iodinated contrast media.
What factors influence surgical decision-making in anterior versus posterior surgery for cervical myelopathy? A QOD analysis
Park, Christine , Shaffrey, Christopher I. , Than, Khoi D. , Michalopoulos, Giorgos D. , Chan, Andrew K. , Bisson, Erica F. , Sherrod, Brandon A. , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Chou, Dean , Chaudhry, Nauman S. , Haid, Regis W., Mummaneni, Praveen V. , Bydon, Mohamad , Gottfried, Oren N., El Sammak, Sally, Michalopoulos, Giorgos , Sammak, Sally El , Park, Paul , Agarwal, Nitin

Mayo Clinic

Journal of Neurosurgery: Spine | November 11, 2023 | Volume: 40 | Issue: 2 | Pages: 206-215

10.3171/2023.8.spine23194 | PMID 37948703 Get It

OBJECTIVE The aim of this study was to explore the preoperative patient characteristics that affect surgical decision-making when selecting an anterior or posterior operative approach in patients diagnosed with cervical spondylotic myelopathy (CSM). METHODS This was a multi-institutional, retrospective study of the prospective Quality Outcomes Database (QOD) Cervical Spondylotic Myelopathy module. Patients aged 18 years or older diagnosed with primary CSM who underwent multilevel (≥ 2-level) elective surgery were included. Demographics and baseline clinical characteristics were collected. RESULTS Of the 841 patients with CSM in the database, 492 (58.5%) underwent multilevel anterior surgery and 349 (41.5%) underwent multilevel posterior surgery. Surgeons more often performed a posterior surgical approach in older patients (mean 64.8 ± 10.6 vs 58.5 ± 11.1 years, p < 0.001) and those with a higher American Society of Anesthesiologists class (class III or IV: 52.4% vs 46.3%, p = 0.003), a higher rate of motor deficit (67.0% vs 58.7%, p = 0.014), worse myelopathy (mean modified Japanese Orthopaedic Association score 11.4 ± 3.1 vs 12.4 ± 2.6, p < 0.001), and more levels treated (4.3 ± 1.3 vs 2.4 ± 0.6, p < 0.001). On the other hand, surgeons more frequently performed an anterior surgical approach when patients were employed (47.2% vs 23.2%, p < 0.001) and had intervertebral disc herniation as an underlying pathology (30.7% vs 9.2%, p < 0.001). CONCLUSIONS The selection of approach for patients with CSM depends on patient demographics and symptomology. Posterior surgery was performed in patients who were older and had worse systemic disease, increased myelopathy, and greater levels of stenosis. Anterior surgery was more often performed in patients who were employed and had intervertebral disc herniation.
Daytime symptom trajectories among adults with stable heart failure and insomnia: evidence from a randomised controlled trial of cognitive behavioural therapy for insomnia
Conley, Samantha , Wang, Zequan , Tocchi, Christine , Linsky, Sarah , O’Connell, Meghan , Conley, Samantha , Jeon, Sangchoon , Redeker, Nancy S.

Mayo Clinic

Journal of Sleep Research | November 7, 2023 | Volume: 33 | Issue: 4 | Pages: No page available

10.1111/jsr.14058 | PMID 37933085 Get It

SummaryPeople with heart failure (HF) experience a high symptom burden and prevalent insomnia. However, little is known about daytime symptom trajectories after cognitive behavioural therapy for insomnia (CBT‐I). In this study we describe: (1) daytime symptom trajectories among adults with insomnia and stable HF over 1 year, (2) how symptom trajectories differ between CBT‐I versus HF self‐management interventions, and (3) associations between demographic, clinical, and sleep characteristics, perceived stress, health‐related quality of life (HRQoL), functional performance and daytime symptoms trajectories. We retrospectively analysed data from a randomised controlled trial of CBT‐I versus HF self‐management (NCT0266038). We measured sleep, perceived stress, HRQoL, and functional performance at baseline and symptoms at baseline, 3, 6, and 12 months. We conducted group‐based trajectory modelling, analysis of variance, chi‐square, and proportional odds models. Among 175 participants (mean [standard deviation] age 63.0 [12.9] years, 57.1% male, 76% White), we found four daytime symptom trajectories: (A) low improving symptoms (38.3%); (B) low psychological symptoms and high improving physical symptoms (22.8%); (C) high improving symptoms (24.0%); and (D) high not improving symptoms (14.9%). The CBT‐I versus the HF self‐management group had higher odds of belonging to Group A compared to other trajectories after controlling for baseline fatigue (odds ratio = 3.27, 95% confidence interval 1.39–7.68). The difference between the CBT‐I and the HF self‐management group was not statistically significant after controlling for baseline characteristics. Group D had the highest body mass index, perceived stress, and insomnia severity and the lowest cognitive ability, HRQoL, and functional performance. Research is needed to further evaluate factors contributing to symptom trajectories.
Personal Actions to Create a Culture of Inclusion: Navigating Difficult Conversations With Medical Colleagues
Sulistio, Melanie S. , Chen, Christine , Eleazu, Ijeoma , Godfrey, Sarah , Abraham, Reeni A. , Toft, Lorrel E.B., Chen, Christine L , Sulistio, Melanie S , Godfrey, Sarah

Mayo Clinic

Annals of Internal Medicine | November 6, 2023 | Volume: 176 | Issue: 11 | Pages: 1520-1525

10.7326/m23-1374 | PMID 37931258 Get It

Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials
Smith, Ashley Wilder , DiMartino, Lisa , Garcia, Sofia F. , Mitchell, Sandra A. , Ruddy, Kathryn J. , Smith, Justin D. , Cahue, September, Cella, David , Jensen, Roxanne E. , Hassett, Michael J. , Hodgdon, Christine, Richardson, Kimberly, Kroner, Barbara L, Yanez, Betina R. , Bian, Jessica , Dizon, Don S. , Hazard‐Jenkins, Hannah , Ahrens, Paige, Barrett, Fiona , Begnoche, Megan, Caron, Kimberly, Coughlin, Ava , Cronin, Christine , Dias, Samira , Farisiv, Nicolas, Flores, Anne Marie, Garcia, Martha, Kircher, Sheetal , Lancki, Nicola , Mai, Quan H, McCleary, Nadine J. , Norton, Wynne E. , O’Connor, Mary , Pachman, Deirdre R. , Pearsonil, Loretta, Podratz, Jewel, Rahman, Parvez, Redmond, Sarah , Reich, James , Schaepe, Karen , Poirier-Shelton, Tiana, Silberman, Philip , Simpson, Jaclyn, Tasker, Laura, Tesch, Nathan , Tramontano, Angela C. , Jensen, Roxanne E , Osarogiagbon, Raymond U , Cheville, Andrea L , Mitchell, Sandra A , Garcia, Sofia F , Wong, Sandra L. , Kroner, Barbara, Osarogiagbon, Raymond U. , Popovic, Jennifer R. , Schrag, Deborah , Cheville, Andrea , Kroner, Barbara L, Griffin, Joan M. , Ardini, Mary-Anne , Austin, Jessica D. , Barrett, Fiona, Bass, Michael , Chlan, Linda L. , Hemming, Karla , Herrin, Jeph , Kroenke, Kurt , Lam, Veronica, Mai, Quan H, Mallow, Jennifer A. , Penedo, Frank J. , Preiss, Liliana , Reich, James, Richardson, Joshua E. , Ridgeway, Jennifer L. , Rutten, Lila J. Finney , Scholtens, Denise M. , Tofthagen, Cindy , Tyndall, Benjamin D. , Uno, Hajime , Wehbe, Firas , Weiner, Bryan Jeffrey

Mayo Clinic

JNCI Cancer Spectrum | November 6, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/jncics/pkad073 | PMID 37930033 Get It

AbstractCancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium’s conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.
Persistent chest pain following COVID‐19 infection – A scoping review
Kubrova, Eva , Klasová, Johana , Rosado, Robert D. Pagan, Prusinski, Christian , Trofymenko, Oleksandr , Schappell, Justin B., Yuh, Clara, Gupta, Sahil , Hallo-Carrasco, Alejandro J, Pagan Rosado, Robert D, Prusinski, Christian C , Hunt, Christine , Hallo‐Carrasco, Alejandro , Prokop, Larry J.

Mayo Clinic

PM&R | October 31, 2023 | Volume: 16 | Issue: 6 | Pages: 605-625

10.1002/pmrj.13098 | PMID 37906499 Get It

AbstractPersistent chest pain (PCP) following acute COVID‐19 infection is a commonly reported symptom with an unclear etiology, making its management challenging. This scoping review aims to address the knowledge gap surrounding the characteristics of PCP following COVID‐19, its causes, and potential treatments. This is a scoping review of 64 studies, including observational (prospective, retrospective, cross‐sectional, case series, and case–control) and one quasi‐experimental study, from databases including Embase, PubMed/MEDLINE, Cochrane CENTRAL, Google Scholar, Cochrane Database of Systematic Reviews, and Scopus. Studies on patients with PCP following mild, moderate, and severe COVID‐19 infection were included. Studies with patients of any age, with chest pain that persisted following acute COVID‐19 disease, irrespective of etiology or duration were included. A total of 35 studies reported PCP symptoms following COVID‐19 (0.24%–76.6%) at an average follow‐up of 3 months or longer, 12 studies at 1–3 months and 17 studies at less than 1‐month follow‐up or not specified. PCP was common following mild—severe COVID‐19 infection, and etiology was mostly not reported. Fourteen studies proposed potential etiologies including endothelial dysfunction, cardiac ischemia, vasospasm, myocarditis, cardiac arrhythmia, pneumonia, pulmonary embolism, postural tachycardia syndrome, or noted cardiac MRI (cMRI) changes. Evaluation methods included common cardiopulmonary tests, as well as less common tests such as flow‐mediated dilatation, cMRI, single‐photon emission computed tomography myocardial perfusion imaging, and cardiopulmonary exercise testing. Only one study reported a specific treatment (sulodexide). PCP is a prevalent symptom following COVID‐19 infection, with various proposed etiologies. Further research is needed to establish a better understanding of the causes and to develop targeted treatments for PCP following COVID‐19.
207 The spatially-resolved proteomic atlas of the tumor immune architecture of HER2-positive breast cancer and response to neoadjuvant anti-HER2 therapy-based chemotherapy
Chumsri, Saranya , Kachergus, Jennifer M., Shi, Ji , Liu, Yi , Ma, Yaohua , Bonnett, Shilah A. , Conner, Mark , Piazza, Erin , Filanoski, Brian, Meredith, Rhonda, Kang, Christine , Isgur, Lesley, Geiss, Gary , Beechem, Joseph , Thompson, E. Aubrey , Rosenbloom, Alyssa B. , Kang, Christine, Hoang, Margaret L.

Mayo Clinic

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A235-A235

10.1136/jitc-2023-sitc2023.0207 Get It

Perceptions Surrounding Cochlear Implants Among At-Risk and Qualifying Older Adults in the United States
Carlson, Matthew L. , Lohse, Christine M. , Marinelli, John P. , Sydlowski, Sarah, Collaborative, Hearing Health

Mayo Clinic

Otology & Neurotology | October 27, 2023 | Volume: 44 | Issue: 10 | Pages: 1021-1026

10.1097/mao.0000000000004041 | PMID 37889933 Get It

Objective Limited evidence to date has examined public perceptions of cochlear implants among adult hearing aid users with moderate to profound hearing loss. The current work was conceived with the chief objective of characterizing the perceptions surrounding cochlear implants among the prospective candidate pool. Study design National cross-sectional survey study. Setting United States. Patients Adults between 50 and 80 years of age with self-reported moderate to moderately severe (n = 200) or moderately severe to profound (n = 200) hearing loss currently using hearing aids. Results The overall survey response rate was 12%. Median age at time of survey for the 400 respondents was 66 years (interquartile range, 60–71 yr) and included 215 (54%) men. In total, 26% did not think of hearing loss as a medical condition, and another 23% were unsure. Overall, 63% of respondents had heard of cochlear implants, but only 2% indicated they were very familiar with them. Despite 52% of respondents reporting “very positive” or “somewhat positive” feelings about cochlear implants, only 9% indicated they were “very likely” to get a cochlear implant in the future, including 7% of those with estimated moderately severe to profound hearing loss at time of survey. Conclusions Even among people with presumed qualifying levels of hearing loss, there exists a widespread lack of familiarity with cochlear implantation as a viable treatment option. This limited awareness seems influenced by a generally poor appreciation for hearing loss as a chronic disease state that warrants treatment. However, among those familiar with cochlear implants, they are generally viewed favorably.
Comparing Speech Recognition Outcomes Between Cochlear Implants and Auditory Brainstem Implants in Patients With NF2-Related Schwannomatosis
Dornhoffer, James R. , Plitt, Aaron , Lohse, Christine M. , Driscoll, Colin L. W., Neff, Brian A., Saoji, Aniket A. , Link, Michael J. , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | October 24, 2023 | Volume: 45 | Issue: 1 | Pages: 29-35

10.1097/mao.0000000000004047 | PMID 37875011 Get It

Objective To compare cochlear implant (CI) and auditory brainstem implant (ABI) performance in patients with NF2-related schwannomatosis (NF2) Study Design Historical cohort. Setting Tertiary academic center. Patients A total of 58 devices among 48 patients were studied, including 27 ABIs implanted from 1997 to 2022 and 31 CIs implanted from 2003 to 2022. Three patients had bilateral ABIs, three had bilateral CIs, three had an ABI on one side and a CI on the other, one had a CI that was later replaced with an ipsilateral ABI, and one had an ABI and CI concurrently on the same side. Interventions CI or ABI ipsilateral to vestibular schwannoma. Main Outcome Measures Open-set speech perception, consonant-nucleus-consonant word scores, and AzBio sentence in quiet scores. Results Among all patients, 27 (47%) achieved open-set speech perception, with 35 (61%) daily users at a median of 24 months (interquartile range [IQR], 12–87 mo) after implantation. Comparing outcomes, CIs significantly outperformed ABIs; 24 (77%) CIs achieved open-set speech perception compared with 3 (12%) ABIs, with median consonant-nucleus-consonant and AzBio scores of 31% (IQR, 0–52%) and 57% (IQR, 5–83%), respectively, for CIs, compared with 0% (IQR, 0–0%) and 0% (IQR, 0–0%), respectively, for ABIs. Patients with ABIs were younger at diagnosis and at implantation, had larger tumors, and were more likely to have postoperative facial paresis. Conclusion Many patients with NF2-associated vestibular schwannoma achieved auditory benefit with either a CI or an ABI; however, outcomes were significantly better in those patients who were able to receive a CI. When disease and anatomy permit, hearing rehabilitation with a CI should be considered over an ABI in these patients. Tumor management strategies that increase the ability to successfully use CIs should be strongly considered given the high risk of losing bilateral functional acoustic hearing in this population.